BAYNES ROY D. sold 9.8% of their position (4.50K shares) of TRAVERE THERAPEUTICS, INC. on the open market
Open‑market sale worth $225.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 6/16/2026ACC: 0001680739-26-000014
-4.50K
Net shares
Net seller
$225.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
4.50K acquired · 9K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+4.50K
Price / share
$21.38
Trade value
$96.21K
% of position
10.8%
6/12/2026
41.50K→46K
Common Stock
Direct
Shares
−4.50K
Price / share
$50.00
Trade value
$225K
% of position
9.8%
6/12/2026
46K→41.50K
Total
Net shares
+0.00
Net value
-$128.79K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/12/2026 | M · Option Exercise | +4.50K | $21.38 | $96.21K | 10.8% | 41.50K | 46K |
| Common Stock Direct | 6/12/2026 | S · Sale | −4.50K | $50.00 | $225K | 9.8% | 46K | 41.50K |
| Total | +0.00 | -$128.79K | ||||||
Derivative Transactions1
Stock option (right to buy)
Direct
Converts to
Common Stock
4.50K shares
Shares
−4.50K
Strike price
21.38
Held after
0.00
Exercisable
—
6/12/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock option (right to buy) Direct | Common Stock4.50K shares | 6/12/2026 | M · Option Exercise | −4.50K | 21.38 | — | 0.00 |